USPSTF cervical cancer screening guidelines
This article was originally published in The Gray Sheet
Executive Summary
Evidence is insufficient to recommend "for or against" use of new screening technologies, including liquid-based cytology, as well as HPV DNA testing, as a primary screen, U.S. Preventive Services Task Force states in guidelines released Jan. 22. While sensitivity generally is increased for liquid-based cytology, more false-positives often result, making it "not clear whether the possible benefits, if any, would be large enough to justify the added costs." USPTF's recommendations on screening intervals and when to start and cease screening are in line with ACS guidelines released in December (1"The Gray Sheet" Jan. 6, 2002, p. 23)...
You may also be interested in...
Cytyc Prepares To Launch ThinPrep Imager; Women’s Health Recap For 2002
Cytyc's ThinPrep and TriPath's SurePath liquid-based cytology Pap tests could receive a boost in 2003 from a positive NICE technology assessment review
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.